Author's response to reviews

**Title:** Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers

**Authors:**

- Sung Min Park (psm7271@naver.com)
- Joomi Lee (joomibbc@hanmail.net)
- Sook-Jin Seong (jv-nee@hanmail.net)
- Jong Gwang Park (freesstyler@hanmail.net)
- Mi-Ri Gwon (babymil1122@hanmail.net)
- Mi-sun Lim (mslim@yu.ac.kr)
- Hae Won Lee (haewonbbc@gmail.com)
- Young-Ran Yoon (yry@knu.ac.kr)
- Dong Heon Yang (ddhyang@knu.ac.kr)
- Kwang-II Kwon (kwon@cnu.ac.kr)
- Seunghoon Han (waystolove@catholic.ac.kr)

**Version:** 2  
**Date:** 21 May 2014

**Author's response to reviews:** see over
May 21, 2014

Dear Christopher Morrey:

This is an original research article entitled “Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers”. On behalf of my colleagues, I would like to submit this manuscript to *BMC Pharmacology and Toxicology*.

In this manuscript, we demonstrated the major parameters to explain the pharmacokinetic and pharmacodynamic characteristics of triflusal in healthy Korean volunteers. In addition, we utilized binary probability model in application to the analysis of qualitative pharmacodynamic endpoint (in this case, inhibition of platelet aggregation) which may be used for further simulation. We believe this approach is an acceptable translation of the early-phase clinical trial data to a certain deductive knowledge for the next step of development and will be of interest to the readers of your journal.

International Committee of Medical Journal Editors (ICMJE) criteria for authorship have been met, and that no person or persons other than the authors listed have contributed significantly to preparation. The contents of this manuscript are our original work and have not been published, in whole or in part, prior to or simultaneous with my submission of the manuscript to *BMC Pharmacology and Toxicology*.

This research was supported by the grants from the National Project for Personalized Genomic Medicine, Ministry of Health & Welfare, Republic of Korea (A111218-PG02); the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (NRF-2013M3A9B6046416); the Pfizer Modeling & Simulation Education Center in Korea (PMECK); and the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (A070001). There is no conflict of interest to be disclosed. Furthermore, this study was approved by the Institutional Review Board of Kyungpook National University Hospital.

We sincerely thank the editor(s) and reviewers for their time in reviewing this submission. We are very
interested in your review of our manuscript. Please contact Seunghoon Han (Phone : +82.2.2258.7326, e-mail: waystolove@catholic.ac.kr) if any questions should arise regarding this submission or during the review process.

Best regards,

Seunghoon Han, MD